Last reviewed · How we verify
OpCT-001
At a glance
| Generic name | OpCT-001 |
|---|---|
| Sponsor | BlueRock Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OpCT-001 CI brief — competitive landscape report
- OpCT-001 updates RSS · CI watch RSS
- BlueRock Therapeutics portfolio CI